Syed Husain is the Chief Executive Officer of BioCentriq, bringing extensive expertise in CDMO development and manufacturing services for both established and emerging modalities. With a career spanning the entire drug development and commercialization lifecycle, Syed has successfully led companies through periods of rapid growth, go-to-market market innovation, and industry disruption. He excels in global business development strategies, enhancing brand visibility, building high-performing teams, optimizing operations, and driving patient-centered, profitable revenue growth.
Prior to joining BioCentriq, Syed was Chief Commercial Officer at Resilience, where he played a key role in building a world-class commercial organization across biologics, vaccines, cell and gene therapies, and nucleic acids. He established a multi-billion-dollar backlog and opportunity pipeline by securing transformative partnerships with leading pharmaceutical and biotech companies. His leadership also fostered a customer-centric culture, supporting sustainable, patient-focused growth. Prior to that, he served in CDMO leadership roles at Emergent BioSolutions, Alcami Corporation and Lonza. He began his career in vaccine manufacturing compliance at Wyeth and across validation, product and process development and manufacturing roles at Pfizer.
Syed holds a Master of Business Administration from Cornell University’s Johnson Graduate School of Management and a Bachelor of Science in Chemical Engineering from the New Jersey Institute of Technology. He serves as an Industrial Advisory Board member for the Otto H York Department of Chemical Engineering at NJIT. He has also served as chair of the Education Committee and on the Advisory Council for the Drug, Chemical & Associated Technologies Association and is involved in the Biotechnology Innovation Organization, Society of Biological Engineers, American Institute of Chemical Engineers and American Chemical Society.
